HCW Biologics Inc. (HCWB) Stock Price & Analysis
HCW Biologics Inc. (HCWB) — price $0.7351 (-3.77%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
HCW Biologics Inc. · HCWB
HCW Biologics Inc. is a preclinical stage biopharmaceutical company focused on developing immunotherapies for chronic inflammation and age-related diseases. Their lead products target cancers, autoimmune diseases, and pulmonary fibrosis.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.7351 |
| Change on the day | -3.77% |
| Shares traded on the day | 10.7K |
Price & events
Other perspectives
Council score for HCW Biologics (HCWB): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is HCW Biologics (HCWB), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. HCW Biologics Inc. (HCWB) is the company analyzed here. It employs 35 people. In Q2 FY2026 it reported revenue of $135,568 and net income of -$5M.
What do the latest results show for HCW Biologics (HCWB)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $135,568. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $135,568 | -$5M | -$43.97 (diluted) |
| Q1 FY2026 | $7M | $4M | $11.82 (diluted) |
| Q4 FY2025 | $27,010 | $719,232 | -$9.90 (diluted) |
| Q3 FY2025 | $15,606 | -$5M | -$12.12 (diluted) |
What are the financial strengths and risks for HCW Biologics (HCWB)?
Short answer · as of
The distress and quality screens read Altman Z -7.24 · Piotroski F 4. Trailing ratios: ROA -18.4% · current ratio 0.06.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -7.24 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 29, 2026
- Transactions
- 3
- Identified insiders
- 3
- Purchases
- 3
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HCWB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HCWB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About HCWB
These answers are editorial: 1 of these 8 answers is drawn from the HCWB research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is HCWB a good stock to buy?
Stock Expert AI does not rate HCWB buy, sell or hold. HCW Biologics Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HCWB stock price today?
The last price recorded for HCW Biologics Inc. (HCWB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for HCWB?
HCWB faces significant risks inherent to preclinical stage biopharmaceutical companies. These include the potential for clinical trial failures, regulatory hurdles in obtaining FDA approval, and competition from larger pharmaceutical companies with greater resources.
What are the key factors to evaluate for HCWB?
Evaluate HCWB on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does HCWB data refresh on this page?
HCWB's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HCWB's recent stock price performance?
HCW Biologics Inc. (HCWB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel immunotherapeutic approach. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HCWB overvalued or undervalued right now?
HCW Biologics Inc. (HCWB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HCWB before investing?
Before investing in HCW Biologics Inc. (HCWB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com